Part D 2010 call letter reissued
Executive Summary
The latest version of the 2010 draft "call letter" to Medicare Part D plan sponsors maintains all the key formulary-related policy statements from the original version, including CMS objections to edits that impede beneficiary access to all approved indications of on-formulary drugs. The draft instructions for submitting bids for 2010 were originally released Jan. 8 (1"The Pink Sheet," Jan. 19, 2009, p. 13). It was withdrawn shortly thereafter by the new administration for review and reissued Jan. 23; comments on the draft are being accepted until March 6 and the final version is scheduled to be released March 30
You may also be interested in...
Part D In 2010: No Reference Pricing, More CMS Scrutiny Of Formulary Edits
The last CMS 1draft "call letter" to Medicare Part D contractors to be issued under the current administration emphasizes familiar themes - concern with information transparency and ensuring appropriate access to drugs - and includes little in the way of drug coverage policy changes
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.